<DOC>
	<DOCNO>NCT00549900</DOCNO>
	<brief_summary>A phase I , open label , single-centre study evaluate safety immunogenicity GlaxoSmithKline Biologicals ' HPV -16/18 L1 VLP AS04 vaccine ( GSK 580299 , Cervarix TM ) , administer intramuscularly accord 0 , 1 , 6-month schedule healthy Chinese female subject age 15 - 45 year . The Protocol Posting update order comply FDA Amendment Act , Sep 2007 .</brief_summary>
	<brief_title>A Single Centre Study Evaluate Safety Immunogenicity Human Papillomavirus Vaccine ( GSK-580299 ) Chinese Females</brief_title>
	<detailed_description>The rationale protocol post amendment change study population 18-35 15-45 year allow subject administer routine vaccine e.g . Hepatitis A &amp; B vaccine , meningococcal vaccine , Tetanus vaccine , Diphteria Tetanus Pertussis etc . 8 day HPV dose .</detailed_description>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects investigator believe comply requirement protocol enrol study . A female Chinese origin , reside China , age 15 45 year ( inclusive ) time first vaccination . Written inform consent obtain subject . For subject legal age consent , write informed consent must obtain subject 's parent Legally Acceptable Representative ( LAR ) , write informed assent must obtain subject . Healthy subject establish medical history clinical examination enter study . Subjects must negative urine pregnancy test . Subjects must nonchildbearing potential , subject childbearing potential , must abstinent must use adequate contraception 30 day prior vaccination continue 2 month completion vaccination series . Use investigational nonregistered product ( drug vaccine ) study vaccine within 30 day precede first dose study vaccine , plan use study period . Pregnant breastfeeding . Planning become pregnant likely become pregnant Chronic administration ( defined 14 day ) immunosuppressant immunemodifying drug within six month prior first vaccine dose . Administration immunoglobulins and/or blood product within three month precede first dose study vaccine plan administration study period . Planned administration/administration vaccine foreseen study protocol within 30 day precede 30 day first dose vaccine . Administration routine vaccine 8 day first dose study vaccine allow . Previous administration component investigational vaccine . Previous vaccination HPV plan administration HPV vaccine foreseen study protocol study period . Any confirm suspected immunosuppressive immunodeficient condition , base medical history physical examination History allergic disease , suspect allergy reaction likely exacerbate component study vaccine . Hypersensitivity latex . Major congenital defect serious chronic illness . History neurologic disorder seizure . Known acute chronic , clinically significant system condition . Cancer autoimmune disease treatment . Acute disease time enrolment . History chronic alcohol consumption and/or drug abuse .</criteria>
	<gender>Female</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>HPV vaccine ,</keyword>
	<keyword>Cervical cancer</keyword>
	<keyword>Human papillomavirus infection ,</keyword>
</DOC>